Search
Close
Search
Advanced Search
Search Menu
AI Discovery Assistant

Extract

Colorectal cancer (CRC) is one of the leading causes of illness and death in the Western world and the second most common cause of cancer morbidity in Europe.1 Yet, if detected early, CRC is highly treatable. Good news has recently arrived from across the Atlantic, where decision analysis tools were employed to inform recommendation updates and ‘microsimulation modelling demonstrated that declines in CRC death rates are consistent with a relatively large contribution from screening’.2

Nevertheless, and despite the fact that U.S. CRC mortality and incidence rates have improved, CRC screening remains underused: only 77.5% of physicians report use of the national screening guidelines and only 51.7% reported recommendations consistent with the guidelines.3 However, there are still European countries without a national population-based CRC screening programme, and even in those with established national screening programmes, they are underutilized. A survey in France, which has an established population-based screening programme, indicated that although 83% of the GPs were convinced of the importance of CRC screening, only 30% recommended the procedure to their patients.4

Issue Section:
Editorial
You do not currently have access to this article.
Download all slides